Cargando…

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs

The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Mellor, H R, Ferguson, D J P, Callaghan, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361565/
https://www.ncbi.nlm.nih.gov/pubmed/16052217
http://dx.doi.org/10.1038/sj.bjc.6602710
_version_ 1782153243585937408
author Mellor, H R
Ferguson, D J P
Callaghan, R
author_facet Mellor, H R
Ferguson, D J P
Callaghan, R
author_sort Mellor, H R
collection PubMed
description The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon adenocarcinoma (DLD-1) cells to mimic the microenvironment of quiescent microregions of solid tumours. The quiescent tumour spheroids (TS(Q)) showed decreased expression of the proliferation marker Ki-67 and increased expression of the quiescence marker p27(kip1) compared to proliferating spheroids (TS(P)). The quiescent status of the TS(Q) was confirmed by long-term growth assessment. The quiescence was completely reversible demonstrating that the TS(Q) retained the ability to proliferate and morphological assessment by light microscopy confirmed the absence of significant apoptosis. When the efficacy of widely used chemotherapeutic drugs was determined, vinblastine, doxorubicin, cisplatin and 5-fluorouracil (5-FU) all produced significant cell death in the TS(P). However, while still effective, the potencies of doxorubicin and cisplatin were significantly reduced in TS(Q). In contrast, 5-FU and vinblastine did not produce cell death in the TS(Q). In summary, TS(Q) show considerable resistance to a panel of established chemotherapeutic agents and represent a useful model for evaluating the efficacy of drugs and other cancer therapies in quiescent tumours.
format Text
id pubmed-2361565
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23615652009-09-10 A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs Mellor, H R Ferguson, D J P Callaghan, R Br J Cancer Translational Therapeutics The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon adenocarcinoma (DLD-1) cells to mimic the microenvironment of quiescent microregions of solid tumours. The quiescent tumour spheroids (TS(Q)) showed decreased expression of the proliferation marker Ki-67 and increased expression of the quiescence marker p27(kip1) compared to proliferating spheroids (TS(P)). The quiescent status of the TS(Q) was confirmed by long-term growth assessment. The quiescence was completely reversible demonstrating that the TS(Q) retained the ability to proliferate and morphological assessment by light microscopy confirmed the absence of significant apoptosis. When the efficacy of widely used chemotherapeutic drugs was determined, vinblastine, doxorubicin, cisplatin and 5-fluorouracil (5-FU) all produced significant cell death in the TS(P). However, while still effective, the potencies of doxorubicin and cisplatin were significantly reduced in TS(Q). In contrast, 5-FU and vinblastine did not produce cell death in the TS(Q). In summary, TS(Q) show considerable resistance to a panel of established chemotherapeutic agents and represent a useful model for evaluating the efficacy of drugs and other cancer therapies in quiescent tumours. Nature Publishing Group 2005-08-08 2005-07-19 /pmc/articles/PMC2361565/ /pubmed/16052217 http://dx.doi.org/10.1038/sj.bjc.6602710 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Mellor, H R
Ferguson, D J P
Callaghan, R
A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
title A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
title_full A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
title_fullStr A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
title_full_unstemmed A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
title_short A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
title_sort model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361565/
https://www.ncbi.nlm.nih.gov/pubmed/16052217
http://dx.doi.org/10.1038/sj.bjc.6602710
work_keys_str_mv AT mellorhr amodelofquiescenttumourmicroregionsforevaluatingmulticellularresistancetochemotherapeuticdrugs
AT fergusondjp amodelofquiescenttumourmicroregionsforevaluatingmulticellularresistancetochemotherapeuticdrugs
AT callaghanr amodelofquiescenttumourmicroregionsforevaluatingmulticellularresistancetochemotherapeuticdrugs
AT mellorhr modelofquiescenttumourmicroregionsforevaluatingmulticellularresistancetochemotherapeuticdrugs
AT fergusondjp modelofquiescenttumourmicroregionsforevaluatingmulticellularresistancetochemotherapeuticdrugs
AT callaghanr modelofquiescenttumourmicroregionsforevaluatingmulticellularresistancetochemotherapeuticdrugs